Tandem Diabetes Care

TNDM on Nasdaq. Tandem Diabetes Care sells insulin pumps and software to people with diabetes. Market value $1.1bn.

Watch this stockFree. We tell you when something changes.

Price checks use the past 12 months to June 2026. Quality checks use five annual reports, the latest for the year to December 2025.

Should I look at this?

Not a fit for our list right now

See Health care stocks that passed both tests

This is not advice. Check the numbers below.

Compare with another stock

Cash yield
past 12 months to June 2026
-2.4%low

For every $100 of what the whole company costs, it produced $-2.37 of spare cash in the past 12 months. A savings account pays about $4.

Price to profit
past 12 months to June 2026
n/a

The filings do not give us enough to work this out.

Return on capital
five annual reports to December 2025
-34.1%five-year median

Each dollar kept in the business earns -34 cents a year. Above 10 is good.

Quality score: 42 of 100. Price score: 0 of 100. Our list needs 70 on quality and 60 on price.

$16.16 a share, 32% above its 1-year low

Over the past year the price has ranged from $12.26 to $29.65.

Pays no dividend

Prices from Tuesday’s close (6 October).

Five years of cash, in billions

0.1
0.0
-0.1
0.0
-0.0
-0.0
2021202220232024202512 monthsto Jun '26
Revenue
$703m$801m$748m$940m$1.0bn
Operating margin
3.2%-11.6%-31.2%-10.5%-18.5%
Debt to equity
n/an/a0.911.332.00
Shares outstanding
0.06bn0.07bn0.07bn0.07bn0.07bn

Health checks

  • Free cash flow positive3 of 5 years
  • Accounting looks honest (Beneish)Nothing unusual
  • Financial strength (Piotroski)4 of 9
  • Profit backed by cash (accruals)No
  • Debt2.00× equity
  • Revenue growth, five yearsStrong, 15.3% a year
  • Buying back its own sharesNo, 8% more shares since 2021

The quarter to June 2026

How the business did, compared with the same quarter a year earlier.

  • Sales: $255 million last quarter, up 6% on a year ago.
  • A loss of $21 million, compared with a loss of $52 million a year ago.
  • It loses 4 cents on each $1 of sales, compared with 20 cents a year earlier.
  • Over the past 12 months it spent $27 million more cash than it brought in, compared with $8 million a year earlier.
  • 3% more shares than a year ago. Each share owns a bit less of the company.
  • Debt is $540 million more than cash, up from $245 million a year ago.
  • Sales grew on a year ago in each of the last 4 quarters.
Sales by quarter
Sales by quarter
Quarter toAmount
September 2024$244m
December 2024$283m
March 2025$234m
June 2025$241m
September 2025$249m
December 2025$290m
March 2026$247m
June 2026$255m
Profit by quarter
Profit by quarter
Quarter toAmount
September 2024-$23m
December 2024$755,000
March 2025-$131m
June 2025-$52m
September 2025-$21m
December 2025-$589,000
March 2026-$20m
June 2026-$21m

From the company's quarterly reports to the SEC.

Dates

Next results (estimated)
n/a
Last annual report (10-K)
19 February 2026
Next quarterly (estimated, 10-Q)
5 November 2026

Who owns it

1 long-term investor we follow owns it, unchanged from 1 last quarter. 274 funds in all.

Jun '25
Dec '25
Jun '26
Largest holders overall

From 13F filings for the quarter ended 30 June 2026.

Big holders and activists

4 investors own more than 5%.

From Schedule 13D and 13G filings: anyone owning more than 5% must file one.

What insiders did

No insider bought shares on the open market in the last 12 months. 1 sold $4,356, $46 of it under preset trading plans.

  • Novara Mark David
    EVP & CHIEF COMMERCIAL OFFICER
    Sold
    Date
    17 March 2026
    Shares
    187
    Price
    $23.05
    Value
    $4,310
  • Novara Mark David
    EVP & CHIEF COMMERCIAL OFFICER
    Sold
    under a preset trading plan
    Date
    5 March 2026
    Shares
    2
    Price
    $22.81
    Value
    $46

From Form 4 filings: insiders must report trades in their own company's shares within two days.

What could go wrong

Cheap for a reason is the question the numbers cannot answer.

Whether the price already reflects the risks is what the deep dive is for.

The deep dive

Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.

  • What the business is worth, as a range, and the margin of safety at today’s price
  • Prices to start buying, buy, and buy hard
  • The three things that would make this a mistake
  • Every number footnoted to the filing it came from
Create a free account to run it

Your first deep dive is free.

What a finished deep dive looks like

Not advice. Numbers on this page come from SEC filings and are updated each night; prices are updated again after the US market closes. The five-year figures are rounded.